NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.

NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.

NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of expression b...

Full description

Bibliographic Details
Main Authors: Foluso O Ademuyiwa, Wiam Bshara, Kristopher Attwood, Carl Morrison, Stephen B Edge, Adam R Karpf, Smith A James, Christine B Ambrosone, Tracey L O'Connor, Ellis G Levine, Anthony Miliotto, Erika Ritter, Gerd Ritter, Sacha Gnjatic, Kunle Odunsi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3386262?pdf=render

Internet

http://europepmc.org/articles/PMC3386262?pdf=render

Similar Items